A combination of glecaprevir and pibrentasvir, hepatitis C meds has been linked to Improved PTSD Symptoms
Editor The findings were published online recently in the American Journal of Epidemiology. Post-traumatic stress disorder (PTSD) is a…
FDA
FDA warned and raises alarm over the dangers of skin-lightening creams
Skin lightening products can be dangerous for consumers when they contain harmful ingredients that are illegal for over-the-counter…
Tinnitus treatment with digital therapy may “rewire” the brain
According to new research, a cell phone software that combines white noise, active game-based therapy, and counselling may…
Januvia, a popular diabetes drug may contain traces of carcinogen
The popular diabetes drug Januvia may contain traces of a probable carcinogen, but patients should keep using the…
First targeted therapy for HER2-Low breast cancer receives FDA approval
The Food and Drug Administration (FDA) has approved targeted therapy for a newly defined subset of breast cancer.…
A novel fusion protein drug for Alzheimer’s disease without inflammatory side effects
Their findings were published on August 4 in Nature Medicine. Although Aduhelm, a monoclonal antibody targeting amyloid beta…
Ruxolitinib cream, the first at-home therapy for Vitiligo, has been approved by the FDA.
The FDA approval is a development that is being cheered by many, but for Tonja Johnson, the founder…
A novel medication encourages the healing of the neurological system in animal models of Stroke
The groundbreaking preclinical study was written by researchers from Case Western Reserve University and UC, and it was…
Intake of an FDA-approved medication, according to researchers, slows the progression of the condition in an Alzheimer’s disease model
The study, recently published in Science Translational Medicine, investigates how niacin modulates microglia response to amyloid plaques in…
An oral medication for a red blood cell dysfunction is approved as a consequence of phase 3 clinical trial findings
The outcomes of the randomised placebo-controlled ACTIVATE trial were released in the New England Journal of Medicine and…
